TEYI PHARMACEUTICAL GROUP CO.,LTD |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 9.52 CNY | -0.10% |
|
-2.36% | -25.62% |
| Apr. 19 | Teyi Pharmaceutical Group Co.,Ltd Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| Mar. 29 | Teyi Pharmaceutical Group Co.,Ltd Approves the Cash Dividend for 2023 | CI |
Valuation
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Capitalization 1 | 4,998 | 6,511 | 4,861 | - | - |
| Enterprise Value (EV) 1 | 4,998 | 6,511 | 4,861 | 4,861 | 4,861 |
| P/E ratio | 28.2 x | 23.3 x | 17.1 x | 13.5 x | 10.9 x |
| Yield | - | 2.79% | 4.43% | 3.97% | 6.9% |
| Capitalization / Revenue | - | 6.1 x | 4.17 x | 3.53 x | 3 x |
| EV / Revenue | - | 6.1 x | 4.17 x | 3.53 x | 3 x |
| EV / EBITDA | - | - | - | - | - |
| EV / FCF | - | - | - | - | - |
| FCF Yield | - | - | - | - | - |
| Price to Book | - | 3.25 x | 2.3 x | 2.15 x | 2 x |
| Nbr of stocks (in thousands) | 434,446 | 508,676 | 510,634 | - | - |
| Reference price 2 | 11.51 | 12.80 | 9.520 | 9.520 | 9.520 |
| Announcement Date | 3/21/23 | 3/7/24 | - | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Net sales 1 | - | 1,067 | 1,165 | 1,378 | 1,619 |
| EBITDA | - | - | - | - | - |
| EBIT 1 | - | 293.3 | 330 | 418 | 516 |
| Operating Margin | - | 27.48% | 28.33% | 30.33% | 31.87% |
| Earnings before Tax (EBT) 1 | - | 293 | 330 | 418 | 516 |
| Net income 1 | 178.2 | 253.2 | 285.2 | 360.9 | 446 |
| Net margin | - | 23.72% | 24.48% | 26.19% | 27.55% |
| EPS 2 | 0.4082 | 0.5500 | 0.5571 | 0.7072 | 0.8714 |
| Free Cash Flow | - | - | - | - | - |
| FCF margin | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - |
| Dividend per Share 2 | - | 0.3571 | 0.4214 | 0.3776 | 0.6572 |
| Announcement Date | 3/21/23 | 3/7/24 | - | - | - |
1CNY in Million2CNY
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - |
| Net Cash position | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - |
| ROE (net income / shareholders' equity) | - | 16.6% | 13.5% | 16% | 18.3% |
| ROA (Net income/ Total Assets) | - | - | 11.3% | 13.1% | 14.9% |
| Assets 1 | - | - | 2,524 | 2,755 | 2,993 |
| Book Value Per Share 2 | - | 3.940 | 4.140 | 4.430 | 4.770 |
| Cash Flow per Share 2 | - | 0.3900 | 0.6400 | 0.7500 | 0.9200 |
| Capex 1 | - | 85.9 | 100 | 100 | 100 |
| Capex / Sales | - | 8.05% | 8.58% | 7.26% | 6.18% |
| Announcement Date | 3/21/23 | 3/7/24 | - | - | - |
1CNY in Million2CNY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
9.52
Average target price
-
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -25.62% | 674M | |
| +34.35% | 693B | |
| +29.39% | 584B | |
| -3.49% | 372B | |
| +20.15% | 332B | |
| +6.19% | 294B | |
| +14.11% | 239B | |
| -3.03% | 211B | |
| +10.02% | 210B | |
| +9.21% | 168B |
- Stock Market
- Equities
- 002728 Stock
- Financials Teyi Pharmaceutical Group Co.,Ltd